Assessment of S-ICD Eligibility With 12-Lead ECG (EL-SID)
Assessment of Subcutaneous Implantable Cardioverter Defibrillator Eligibility With 12-lead Electrocardiogram
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health and Science University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- medical condition, predisposing patient to life-threatening ventricular arrhythmias, eligible for currently approved ICD indications for primary or secondary prevention of sudden cardiac death
Exclusion Criteria:
- Acute medical condition (e.g. acute myocardial infarction, severe trauma, post-surgery, admitted to ICU)
- End stage organ failure
- Pregnancy
- Patient, legal guardian or authorized representative is unable or unwilling to cooperate or give written informed consent
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Cross-Sectional
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Amplitudes of R- and T-waves (and R/T ratios) on a special precordial ECG
Time Frame: at the day of ECG recording (cross-sectional study)
|
Amplitudes of R- and T-waves (and R/T ratios) on a special ECG (recorded for Subcutaneous ICD eligibility assessment)
|
at the day of ECG recording (cross-sectional study)
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Thomas JA, Perez-Alday EA, Hamilton C, Kabir MM, Park EA, Tereshchenko LG. The utility of routine clinical 12-lead ECG in assessing eligibility for subcutaneous implantable cardioverter defibrillator. Comput Biol Med. 2018 Nov 1;102:242-250. doi: 10.1016/j.compbiomed.2018.05.002. Epub 2018 May 8.
- Wang L, Javadekar N, Rajagopalan A, Rogovoy NM, Haq KT, Broberg CS, Tereshchenko LG. Eligibility for subcutaneous implantable cardioverter-defibrillator in congenital heart disease. Heart Rhythm. 2020 May;17(5 Pt B):860-869. doi: 10.1016/j.hrthm.2020.01.016.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- STUDY00016034
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Implantable Defibrillator User
-
NCT05349162CompletedImplantable Defibrillator User | Implantable Cardioverter Defibrillator Complications
-
NCT05116176Enrolling by invitationImplantable Defibrillator User
-
NCT02787291Completed
-
NCT02491853CompletedImplantable Defibrillator User
-
NCT04858672RecruitingImplantable Defibrillator User | Implantable Defibrillator Lead Dysfunction | Implantable Automatic Defibrillator Malfunction
-
NCT06937658RecruitingPacemaker DDD | Implantable Defibrillator User
-
NCT02902458CompletedImplantable Defibrillator User